- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Menarini, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides. (Pubmed Central) - Mar 27, 2024
This includes Staphylococcus aureus, both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, coagulase-negative Staphylococci (CoNS), streptococci, and vancomycin-sensitive Enterococcus faecalis...This is attributed to their unique pharmacologic and pharmacokinetic characteristics. More quality data (i.e., number of patients treated with clinical success) are needed before clinicians may use these therapies more widely.
- |||||||||| Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
PK/PD data, Review, Journal: Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges. (Pubmed Central) - Mar 1, 2024
Concomitant opioid substitution therapy and other factors, such as malnutrition, contribute to altered pharmacokinetics/pharmacodynamics, emphasizing the importance of targeted therapeutic drug monitoring. Overall, our study calls for increased awareness among clinicians regarding the unique pharmacokinetic/pharmacodynamic challenges in IVDUs and advocates for tailored antibiotic dosing strategies to enhance treatment outcomes in this marginalized population.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Recurrent bacteremia and endocarditis due to Staphylococcus capitis in a patient with Bowen's disease: a case report. (Pubmed Central) - Feb 20, 2024
The patient's clinical journey encompassed multiple hospital admissions, with challenges in managing endocarditis, pacemaker replacements, and potential cutaneous sources of infection. The treatment regimen included intravenous antibiotic therapy during hospitalization and suppressive antibiotic treatment upon discharge, alongside a decolonization strategy for his scalp lesions.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal: In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. (Pubmed Central) - Feb 7, 2024
The treatment regimen included intravenous antibiotic therapy during hospitalization and suppressive antibiotic treatment upon discharge, alongside a decolonization strategy for his scalp lesions. In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal, Adherence: Dalbavancin Use in Persons Who Use Drugs May Increase Adherence Without Increasing Cost. (Pubmed Central) - Feb 6, 2024
The contribution margin with DAL use was $7180 compared with $6655 without; this was not statistically significant (P = 0.47). Dalbavancin use in PWUD may increase treatment completion, with no statistically significant difference in contribution margins.
- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Arbelic (telavancin) / Cumberland, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods. (Pubmed Central) - Feb 2, 2024
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is widely recognized as the gold standard for measuring small molecules, such as antibiotics. This review provides a comprehensive overview of LC-MS/MS methods available for TDM of glycopeptide antibiotics, including vancomycin, teicoplanin, dalbavancin, oritavancin, and telavancin.
- |||||||||| Review, Journal, Gram positive: Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician? (Pubmed Central) - Jan 26, 2024
Several antibiotics are now available to treat these drug-resistant pathogens, such as daptomycin, dalbavancin, linezolid, tedizolid, ceftaroline, ceftobiprole, and fosfomycin...We reviewed the available evidence about the epidemiology of antibiotic resistance to these antibiotics and the main molecular mechanisms of resistance, particularly methicillin-resistant Sthaphylococcus aureus, methicillin-resistant coagulase-negative staphylococci, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus pneumoniae...We focused on the risk of the emergence of resistance during treatment, particularly for daptomycin and fosfomycin, and we discussed the strategies that can be implemented to reduce this phenomenon, which can lead to clinical failure despite appropriate antibiotic treatment. The judicious use of antibiotics, epidemiological surveillance, and infection control measures is essential to preserving the efficacy of these drugs.
- |||||||||| Review, Journal: New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections. (Pubmed Central) - Jan 22, 2024
The halogenated tetracycline eravacycline does not reach CSF concentrations sufficient to treat colistin-resistant Gram-negative bacteria with usual intravenous dosing...An additional IVT can overcome the limited penetration of many new antibiotics into CSF. It should be considered for patients in which the CNS infection responds poorly to systemic antimicrobial therapy alone.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience. (Pubmed Central) - Jan 22, 2024
In conclusion, Cmax-based TDM was associated with a significant reduction in the inter-individual variability of dalbavancin concentrations and lower drug dosing frequency than those of Cmin-based TDM. This approach could, therefore, favor a more rational and targeted use of dalbavancin in patients requiring prolonged treatment.
- |||||||||| Review, Journal: Novel drug candidates against antibiotic-resistant microorganisms: A review. (Pubmed Central) - Jan 18, 2024
In addition to these identified drug candidates, continued in vitro and in vivo studies are required to investigate small molecules with potential antibacterial effects screened by computational receptor docking. As drug discovery progresses, preclinical and clinical studies should also be extensively conducted on the currently available therapeutic agents to unravel their potential antibacterial effect and spectrum of activity, as well as safety and efficacy profiles.
- |||||||||| Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Is Corynebacterium striatum an emerging prosthetic joint infection pathogen and how should it be treated? (Pubmed Central) - Dec 25, 2023
It is important for clinicians to be cognizant that this pathogen can have inducible high level daptomycin resistance and that daptomycin is likely not a reliable antibiotic for these infections. While vancomycin and linezolid are the traditional antibiotics to use in these infections, other antibiotics such as dalbavancin, may also have utility, but more research is needed to determine the effectiveness of this antibiotic in C. striatum infections.
- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie, Zeftera (ceftobiprole) / Basilea
Review, Journal: New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended. (Pubmed Central) - Dec 23, 2023
Furthermore, an old antibiotic, fosfomycin, has gained renewed interest for the treatment of complicated infections such as IE. In this narrative review, we focused on new antimicrobials and therapeutic strategies that we believe may provide important contributions to the advancement of Gram-positive IE treatment, providing a summary of the current in vitro, in vivo, and clinical evidence supporting their use in clinical practice.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal: De Betekenis van huisdieren in de langdurige thuiszorg. (Pubmed Central) - Dec 12, 2023
Also, a cost reduction was detected, due to a significant shortness of hospital stay. Resultaten: De review bevatte vijftien artikelen die achtentwintig rollen gerelateerd aan de betekenis van huisdieren beschreven, onderverdeeld in zeven categorie
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date: COPAT: Comparing Oral Versus Parenteral Antimicrobial Therapy (clinicaltrials.gov) - Dec 11, 2023
P4, N=135, Enrolling by invitation,
Resultaten: De review bevatte vijftien artikelen die achtentwintig rollen gerelateerd aan de betekenis van huisdieren beschreven, onderverdeeld in zeven categorie Not yet recruiting --> Enrolling by invitation | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: The role of long-acting antibiotics in the clinical practice: a narrative review. (Pubmed Central) - Dec 11, 2023
Registration studies confirmed non-inferiority of long-acting glycopeptides to standard of care in ABSSSI (dalbavancin DISCOVER 1 and 2: 79.7% clinical success in the dalbavancin group and 79.8% in the vancomycin-linezolid group; oritavancin SOLO I: 82,3% clinical success in the oritavancin group versus 78,9% for the vancomycin group; SOLO II: 80,1% clinical success versus 82,9%)...However, the low penetration in cerebrospinal fluid of dalbavancin and the unfavourable outcomes in the only case report of oritavancin treatment in human meningitis despite encouraging animal models would seem to make these molecules unsuitable for central nervous system infection therapy. Most of the available evidence is based on small retrospective cohorts, so robust prospective studies investigating off-label indications are needed.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Observational data, PK/PD data, Journal: Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study. (Pubmed Central) - Dec 4, 2023
Most of the available evidence is based on small retrospective cohorts, so robust prospective studies investigating off-label indications are needed. Plasma concentrations of dalbavancin were consistent with those described in clinical trials and those sought during the industrial development of the molecule.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal, Gram positive: Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections. (Pubmed Central) - Nov 30, 2023
The use of biweekly dalbavancin infusions in our 8 patients prevented infection for an extended period of time despite some of the patients not being able to consistently receive infusions. Larger studies are needed to determine the efficacy and safety of using dalbavancin for long-term suppression of gram-positive LVAD infections.
- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Baxdela (delafloxacin) / Menarini, Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Current approach to skin and soft tissue infections. Thinking about continuity of care. (Pubmed Central) - Nov 28, 2023
New anionic fluoroquinolones (e.g. delafloxacin), highly active in an acidic medium and with the possibility of switch from the intravenous to the oral route, will also make it possible to achieve these new healthcare goals and promote continuity of care. Therefore, management should rely on a collaborative multidisciplinary group with experience in this infectious syndrome.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Phase classification, Head-to-Head: DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Nov 13, 2023
P2, N=200, Active, not recruiting,
This case series seems to suggest a promising role of long-term suppressive dalbavancin treatment for difficult-to-treat cardiovascular prosthesis infection, also with limited surgical indications. Phase classification: P2b --> P2
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Persoonsgerichte zorg in de praktijk. (Pubmed Central) - Oct 30, 2023
For highly selected patients with sternal osteomyelitis for whom surgery is a too risky option, an approach including the contribution of various specialists might be a viable way out. Vijf zorgprofessionals en zeven naasten van bewoners met dementie zijn hierover ge
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. (Pubmed Central) - Oct 27, 2023
Clinical studies have shown its non-inferiority compared to conventional therapies in BJI, offering potent activity against key pathogens and an extended dosing interval that may shorten hospitalization. In conclusion, dalbavancin represents a promising treatment option for BJI with a favorable safety profile, but further research in both adults and particularly children, who are ideal candidates for long-acting antibiotics, is necessary to evaluate the role of dalbavancin in BJI.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal, Gram positive: Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. (Pubmed Central) - Oct 22, 2023
Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Gram positive: SUDDEN-OUT: Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition (clinicaltrials.gov) - Oct 19, 2023
P2/3, N=11, Terminated,
Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections. N=60 --> 11 | Trial completion date: Apr 2024 --> Oct 2023 | Enrolling by invitation --> Terminated | Trial primary completion date: Apr 2024 --> Oct 2023; Delays in recruitment due to COVID-19 and higher than acceptable loss to followup.
|
